RT Journal Article
T1 The Genotype of the Donor for the (GT)n Polymorphism in the Promoter/Enhancer of FOXP3 Is Associated with the Development of Severe Acute GVHD but Does Not Affect the GVL Effect after Myeloablative HLA-Identical Allogeneic Stem Cell Transplantation.
A1 Noriega, Víctor
A1 Martínez-Laperche, Carolina
A1 Buces, Elena
A1 Pion, Marjorie
A1 Sánchez-Hernández, Noemí
A1 Martín-Antonio, Beatriz
A1 Guillem, Vicent
A1 Bosch-Vizcaya, Anna
A1 Bento, Leyre
A1 González-Rivera, Milagros
A1 Balsalobre, Pascual
A1 Kwon, Mi
A1 Serrano, David
A1 Gayoso, Jorge
A1 de la Cámara, Rafael
A1 Brunet, Salut
A1 Rojas-Contreras, Rafael
A1 Nieto, José B
A1 Martínez, Carmen
A1 Gónzalez, Marcos
A1 Espigado, Ildefonso
A1 Vallejo, Juan C
A1 Sampol, Antonia
A1 Jiménez-Velasco, Antonio
A1 Urbano-Ispizua, Alvaro
A1 Solano, Carlos
A1 Gallardo, David
A1 Díez-Martín, José L
A1 Buño, Ismael
K1 Anciano
K1 Femenino
K1 Adulto
K1 Factores de transcripción en cabeza de tenedor
K1 Estudios de asociación genética
K1 Genotipo
K1 Enfermedad injerto contra huésped
K1 Efecto injerto contra leucemia
K1 Trasplante de células madre hematopoyéticas
K1 Humanos
K1 Masculino
K1 Mediana edad
K1 Polimorfismo genético
K1 Regiones promotoras genéticas
K1 Análisis de supervivencia
K1 Donantes de tejidos
K1 Trasplante homólogo
AB The FOXP3 gene encodes for a protein (Foxp3) involved in the development and functional activity of regulatory T cells (CD4+/CD25+/Foxp3+), which exert regulatory and suppressive roles over the immune system. After allogeneic stem cell transplantation, regulatory T cells are known to mitigate graft versus host disease while probably maintaining a graft versus leukemia effect. Short alleles (≤(GT)15) for the (GT)n polymorphism in the promoter/enhancer of FOXP3 are associated with a higher expression of FOXP3, and hypothetically with an increase of regulatory T cell activity. This polymorphism has been related to the development of auto- or alloimmune conditions including type 1 diabetes or graft rejection in renal transplant recipients. However, its impact in the allo-transplant setting has not been analyzed. In the present study, which includes 252 myeloablative HLA-identical allo-transplants, multivariate analysis revealed a lower incidence of grade III-IV acute graft versus host disease (GVHD) in patients transplanted from donors harboring short alleles (OR = 0.26, CI 0.08-0.82, p = 0.021); without affecting chronic GVHD or graft versus leukemia effect, since cumulative incidence of relapse, event free survival and overall survival rates are similar in both groups of patients.
PB Public Libray of Science
YR 2015
FD 2015-10-16
LK http://hdl.handle.net/10668/2284
UL http://hdl.handle.net/10668/2284
LA en
NO Noriega V, Martínez-Laperche C, Buces E, Pion M, Sánchez-Hernández N, Martín-Antonio B, et al. The Genotype of the Donor for the (GT)n Polymorphism in the Promoter/Enhancer of FOXP3 Is Associated with the Development of Severe Acute GVHD but Does Not Affect the GVL Effect after Myeloablative HLA-Identical Allogeneic Stem Cell Transplantation. PLoS One. 2015; 10(10):e0140454
NO Journal Article; Research Support, Non-U.S. Gov't;
DS RISalud
RD Apr 10, 2025